Upsher-Smith to Acquire Proximagen

The acquisition provides Upsher-Smith Laboratories with expanded R&D capabilities.

Upsher-Smith Laboratories agreed to acquire Proximagen, a company focused on therapeutics for central nervous system (CNS) diseases.

Upsher-Smith intends to integrate operations in Cambridge and London, U.K. The acquisition provides Upsher-Smith with expanded R&D capabilities. Proximagen’s pipeline contains a number of programs in various stages of development across a breadth of therapeutic classes including CNS, inflammation, oncology, and ophthalmology. Its most advanced candidate is Phase II-stage PRX00933 for obesity and type 2 diabetes. In Phase I/II are naluzotan and tonabersat for treatment of refractory epilepsy patients and sabcomeline for cognition in schizophrenia.

Upsher-Smith’s central nervous system pip